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Abstract: The UK is a global leader in stop-smoking support—providing free behavioral support
and cessation medication via stop smoking services (SSS) without charge to smokers. This study
aimed to explore the client and service characteristics associated with abstinence 52 weeks after
quitting. A prospective cohort study of 3057 SSS clients in nine different areas of England who began
their quit attempt between March 2012 and March 2013 was conducted. Important determinants of
long-term quitting were assessed through quit rates and multivariable logistic regression. Our results
showed that the overall weighted carbon monoxide validated quit rate for clients at 52 weeks
was 7.7% (95% confidence interval (CI) 6.6–9.0). The clients of advisors, whose main role was
providing stop-smoking support, were more likely to quit long-term than advisors who had a
generalist role in pharmacies or general practices (odds ratio (OR) 2.3 (95% CI 1.2–4.6)). Clients were
more likely to achieve abstinence through group support than one-to-one support (OR 3.4 (95% CI
1.7–6.7)). Overall, one in thirteen people who set a quit date with the National Health Service (NHS)
Stop-Smoking Service maintain abstinence for a year. Improving abstinence is likely to require a
greater emphasis on providing specialist smoking cessation support. Results from this study suggest
that over 18,000 premature deaths were prevented through longer-term smoking cessation achieved
by smokers who accessed SSS in England from March 2012 to April 2013, but outcomes varied by
client characteristic and the type of support provided.
Keywords: smoking cessation; stop-smoking services; smoking cessation services; behavioural
support; pharmacotherapy
1. Introduction
The UK stop-smoking services (SSS) have aimed to reduce smoking-related deaths, particularly
from cancer and coronary heart disease, which predominantly occur among disadvantaged
groups since 1999 [1,2]. SSS provide behavioural support delivered by trained practitioners and
pharmacotherapy. SSS clients are routinely followed up four weeks after they have set a quit date.
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Self-report and carbon monoxide (CO) tests are undertaken. Previous studies have shown that the
services reach large numbers, achieve a substantial impact and are cost effective [3–5]. Recent routine
data from the SSS in England show that 35% of service users achieve Russell standard carbon monoxide
abstinence four weeks after their quit date (the date at which they agree with the services that they
will stop smoking), which equates to 72,111 four-week quitters per year [6]. Measuring longer-term
abstinence is resource intensive due to growing lost to follow-up rates and thus the English services
do not have the capacity for long-term follow-up [7].
The English SSS are based on a body of evidence surrounding optimal smoking cessation
techniques, with ongoing audit and evaluation [8–10]; two previous studies collected long-term
(52-week) follow-up data from UK SSS. The first of these was conducted in 2002 in Nottingham and
North Cumbria. Fifteen percent of 2069 clients had been abstinent for a year and were CO validated
after one year [7]. In 2007 data from 1374 pharmacy services and 411 closed group clients in Glasgow
were collected. The CO validated quit rate at 12 months was 2.8% for the pharmacy service and
6.3% for the closed groups. Nevertheless, both types of service were found to be cost effective [3].
Other than England, the UK nations attempt to collect 52-week self-report follow-up data.
During the financial year April 2012 to March 2013, the Welsh services, where clients mostly attend
closed groups, had the highest quit rate (32%) but the lowest reach (6299 clients) [11] whereas the
Scottish services, which are 75% pharmacy led, had the lowest quit rate (6%) but a reach of 116,198 quit
attempts [12]. The Northern Irish services have an intermediate reach (32,714 quit attempts) and a
quit rate of 17% (for 2011/2012, latest data available) [13]. For comparison, 724,247 quit attempts were
made with the English services 2012/2013 [14] with no national data on 52-week outcome.
In 2011, the English Department of Health commissioned a new study to examine longer-term
abstinence among clients of the English SSS: ‘Evaluating longer-term outcomes of the National Health
Service (NHS) Stop Smoking Services’ (ELONS). It was commissioned for two key reasons. First, was to
fill an evidence gap (there has been no comprehensive, independent evaluation of English stop-smoking
services’ long-term outcomes for a decade). Second, the configuration of the stop-smoking services
has changed markedly (group support has declined in favour of one-to-one support [6,14] and a
growing proportion of SSS clients received support from non-specialist practitioners. These are people
whose main job is providing general NHS care but who have had some training to also provide SSS
behavioural support. Usually non-specialist advisors are general practice (GP) nurses, healthcare
assistants, pharmacists, and pharmacy assistants [15–18]. It is important to assess whether these
changes could influence longer-term outcomes.
2. Materials and Methods
Ethical approval was obtained in June 2011 from NHS Lothian (South East Scotland Research
Ethics Committee 2003). The research took place in nine areas of England: Bristol; County Durham
and Darlington; Hull and East Riding; Leicestershire County and Rutland; North and North East
Lincolnshire; Northamptonshire; Oldham; Rotherham; and South East Essex. Services in these areas
were asked to participate because they encompassed a range of behavioural support types, short-term
success rates, urban and rural locations [19] and they used QuitManager (North 51, Nottingham,
UK) [20] for routine monitoring data management (so electronic data on participants’ characteristics in
a standard format was available to the research team). General practices (NHS provided centres of
family medicine) and pharmacies (private companies which dispense medicines) with staff who were
trained SSS advisors within these areas were also asked to participate in the study.
SSS clients who set a quit date, were not pregnant and aged 16 years or over, were recruited
to the study between March 2012 and March 2013; the majority (77%) between July and November.
Clients attended a number of behavioural support sessions with a trained advisor and pharmacotherapy
was available. Additional data were collected from participating clients on sociodemographic
characteristics, health and wellbeing, smoking behaviour, pharmacotherapy and behavioural support
type. These data were collected either by advisors (seven sites) and entered directly into QuitManager
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or, where sites did not have the capacity for advisors to collect additional data, by a Primary Care
Research Network (PCRN) researcher on paper which was then manually entered by the research team.
Self-reported quitters at four weeks were contacted by TNS-BMRB (a social research company,
Westgate, London, UK) 52 weeks after they had set a quit date and asked to complete a short telephone
questionnaire about their smoking status. Those that reported not smoking in the last seven days were
asked if they would participate in a CO monitoring test at their home. At least three attempts were
made to contact each client, at different times of day, before they were classified as lost to follow-up.
The 52-week follow-up and descriptive information were combined in an anonymised database
for analysis. Sample representativeness of the sample and weight creation required a comparison of
the ELONS sample with a dataset including every client, not just those who participated in ELONS,
from the nine participating services. These clients had a quit date set during the recruitment period
(March 2012 to March 2013). The dataset was provided by North51 with a limited selection of client
characteristics, service characteristics and four-week quit data that is routinely collected.
We also had access to the datasets of two aforementioned previous long-term evaluations of the
UK Stop Smoking Services: the Nottingham/North Cumbria study in 2002 [7] and Glasgow in 2007 [3].
Quit rates and follow-up rates from these studies were compared with the ELONS study.
2.1. Sample
Data on 3075 quit attempts were collected, six clients (0.2%) were excluded due to pregnancy
and 12 (0.4%) were excluded because details about the client’s behavioural support advisor were not
recorded in the database. The final study sample (n = 3057) represents 5% of all those recorded as
using the English SSS services during the recruitment period (March 2012 to March 2013). Of these
3057 cases, 1729 (56.6%) self-reported four-week abstinence and were eligible for 52-week follow-up.
2.2. Measures
Characteristics studied include design variables, demographic variables, socioeconomic
status (SES); health and wellbeing, dependence on tobacco, support, determination to quit;
and pharmacotherapy.
2.2.1. Design Variables
Design variables needed to be included in all regression models because of differences between
the study sample and the client base of the services: we deliberately oversampled clients who received
behavioural support in a group setting in order to have sufficient cases for analysis. General practices
and pharmacies proved difficult to recruit to the study, some services recruited higher proportions of
their clients than others and services recruited over different time periods. We included six different
forms of behavioural support, four forms were run by specialist advisors: open groups, where clients
can join the group at any time; closed groups, where clients start the course together and new clients are
not added to the group after the first session; one-to-one sessions, where clients meet individually with
an advisor; and drop-ins where clients can attend without previously making an appointment. The fifth
form of behavioural support is provided in general practices and the advisors are general practice
employees who do smoking cessation work as one of many tasks. The sixth form of behavioural
support took place in pharmacies and the advisors were pharmacy staff who again provide smoking
cessation advice alongside other tasks. The locations were nine areas of England. Attendance at
SSS varies with time of year, thus we separated clients who attended after Christmas (January and
February) which tend to be busy months with high quit rates from those who attended in the quiet
months in the Summer (July and August) and who attended after the summer break (September and
October) from those who attended in other months.
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2.2.2. Socio-Demographic Variables
We recorded age, gender and ethnicity to measure demography. To measure socioeconomic
status, we created a variable which counted the number of the following indicators of disadvantage:
(1) routine or manual occupation or unemployed or permanently sick; (2) basic (general certificate
of secondary education, GCSE) or no education; (3) social or private renting; (4) eligible for free
prescriptions; (5) single parent. We contrasted clients with 0 to 1 indicators of disadvantage with
clients with three to five indicators of disadvantage. We have used similar methodology for deriving
an overall SES measure from a plethora of indicators in previous evaluations of SSS [7,21,22].
2.2.3. Health and Wellbeing
Low levels of mental wellbeing have been associated with low cessation rates [23]. We used the
WHO-Five wellbeing scale [24] to measure health and wellbeing. This is a validated, internationally
used, five item, Likert type scale which measures hedonic (emotional) and eudemonic (meaning)
aspects of subjective wellbeing [25]. Responses to the five items are summed to produce a wellbeing
score. A higher score indicates higher wellbeing.
2.2.4. Dependence on Tobacco, Support and Determination to Quit
Measures of smoking related characteristics included dependence. Clients who smoked within
five minutes of waking or who smoked more than 30 cigarettes a day were classified as dependent.
We measured support through two variables: whether clients had support from a spouse or
partner for their quit attempt and whether half or more of their family and friends did not smoke.
Clients who said that they were extremely or very determined to quit were classified as determined
to quit.
2.2.5. Medication
The medication given varied between locations. As it was necessary to include location in
the model for sampling reasons, we were only able to include whether clients took varenicline,
a particularly effective medication [26,27].
2.2.6. Potential Confounders Excluded
The following characteristics were not used in the analysis due to a non-significant association with
quitting smoking and/or multicollinearity in preliminary testing: marital status, medical conditions,
some medication types (single nicotine replacement therapy (NRT), multiple NRT, bupropion (services
medication regimens differed widely so there was collinearity with medication)), how introduced to
the services, previous quit attempt, advisor type, and intervention setting.
2.2.7. Outcomes
The main outcome, consistent with the Russell Standard [28], was CO validated quitting at
52 weeks, as a proportion of everyone who tried to quit. We took an intention-to-treat approach, thus
clients who were lost to follow-up were counted as smoking. Thus, we were able to include all clients
present at baseline in the analysis of long-term quitting.
The Russell Standard allows clients to still be counted as continuously abstinent (or quit at
52 weeks) if they have smoked up to five cigarettes during the abstinence period. For completeness,
we also calculated various alternatives: a stricter quit rate which does not allow any lapses (known
as ‘not a puff’ [29]) and a more lenient quit rate (known as ‘point prevalence’ [30]) which only asks
whether the client has smoked within the past seven days.
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2.3. Procedure
Firstly, CO validated and self-report quit rates and follow-up statistics were calculated and
tabulated with the Nottingham/North Cumbria 2002 data and the Glasgow 2007 data.
Secondly, for each characteristic, raw and weighted 52-week CO validated quit rates were
calculated. As a result of the low participation rate, the sample was rim-weighted to the characteristics
of the population of clients who passed through the nine participating services between March 2012
and March 2013. The variables used for weighting were behavioural support type, age, gender and
SES (National Statistics Socio-Economic Classification (NS-SEC) [31]).
Quit rates were then calculated using weighted data and accounting for clustering by location.
SPSS (v21) (IBM, New York, NY, USA) was used to calculate the raw quit rates and Stata (v13)
(StataCorp LP, College Station, TX, USA) was used to calculate corrected quit rates and 95% confidence
intervals (CI).
Thirdly, the relationships between CO validated quitting, personal and stop-smoking service
characteristics were investigated with logistic regression analysis using SPSS (v21). Initially, multilevel
models were created with the client at level 1 and the advisor at level 2. However, due to lack of
variance at level 2 (between advisors) the multilevel models were redundant; therefore, standard
logistic regression models were used, with design variables and sociodemographic variables (with the
exceptions of ethnicity and wellbeing) included as a priori variables. For the other predictors (including
ethnicity and wellbeing) a backwards stepwise elimination procedure was used. Multicollinearity was
tested by entering each predictor into the model alone and comparing the standard error with the final
model. An increase greater than 5% was taken as indicating a concerning level of multicollinearity [32].
None of the variables in the final model had indications of multicollinearity. Model robustness was
tested by adding variables that had been non-significant in preliminary modelling of four-week
outcomes: how introduced to service, medication type (which was substituted for the medication
variable), health and wellbeing alternatives (substituted for the wellbeing WHO-Five score) and marital
status. None of these reached significance.
3. Results
3.1. Smoking Status
Less than one quit attempt in 10 (9.3%) was CO validated as achieving long-term abstinence
(consistent with the Russell Standard), rising to 14.7% with the inclusion of self-reported cases without
CO validation (Table 1). There were 41.7% who were not long-term abstinent (which included
0.8% where the CO validation was challenged by a CO ≥10 parts per million test), with a further
43.6% lost to follow-up. Short-term (four-week) abstinence was achieved by 57% of clients. Follow-up
was achieved for 34% of baseline clients. Ten percent were given CO validation tests. The CO validated
point prevalence quit rate was 18.3% and the quit rate including only clients who stated they had not
had any cigarettes (“not a puff”) was 12.8%.
The long-term abstinence rate was intermediate between the Nottingham/North Cumbria
evaluation (14.6%) and the Glasgow evaluation (3.6%). Follow-up losses were smaller in the former
and larger in the latter study.
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Table 1. Quit rates and follow-up rates.
Nottingham/North
Cumbria (n = 2069)
2002 N (%)
Glasgow (n = 1785)
2007 N (%)
ELONS 1 (n = 3057)
2012/2013 N (%)
52 weeks follow-up (Russell Standard):
1 CO validated quit (0–5 cigarettes since quit date) 303 (14.6) 64 (3.6) 285 (9.3)
2 Self report not CO validated 65 (3.1) 63 (3.5) 165 (5.4)
3 Self report refuted by CO validation 8 (0.4) 1 (0.1) 25 (0.8)
4 Non-quitters at 52 weeks 525 (25.4) 264 (14.8) 578 (18.8)
5 Non-quitters at 4 weeks 392 (18.9) 259 (14.5) 681 (22.1)
6 Lost to follow-up at 52 weeks 367 (17.7) 179 (10.0) 689 (22.4)
7 Lost to follow-up at 4 weeks 409 (19.8) 955 (53.5) 653 (21.2)
Total 52-week self-report (excluding refuted by CO test) 368 (17.7) 127 (7.1) 450 (14.7)
Alternative self-report quit rates at 52 weeks 2
Point prevalence 3 NA 131 (7.3) 558 (18.3)
Continuous abstinence (not a puff) 377 (18.2) 108 (6.1) 390 (12.8)
Alternative CO validated quit rates at 52 weeks
Point prevalence 3 NA NA 348 (11.4)
Continuous abstinence (not a puff) 303 (14.6) 62 (3.5) 260 (8.5)
Total eligible for follow-up at 52 weeks (all 4 weeks self-report) 1272 (61.5) 568 (31.8) 1735 (56.7)
Total successfully followed up at 52 weeks 901 (43.5) 392 (22.0) 1051 (34.4)
Total eligible for CO validation at Russell standard 376 (18.2) 128 (7.2) 475 (15.5)
Total given CO test 311 (15.0) 65 (3.6) 310 (10.1)
CO validated quit rate of those successfully followed up 34.5% 16.1% 27.1%
1 Unweighted; 2 These include all self-report (includes refutes); 3 Whether not smoked within: ELONS the last
7 days, Glasgow last 2 weeks. CO: carbon monoxide; NA: not applicable. This table is reproduced from the
project report [33].
3.2. Fifty-Two-Week Quit Rates and Multivariable Odds Ratios for Predicting Quitting for Various
Client Groups
3.2.1. Sample Design Characteristics
The weighted quit rate reduced to 7.7% (95% CI 6.6–9.0) from a raw quit rate of 9.3% (Table 2).
For analysis purposes, open and closed groups and non-specialist general practitioner and pharmacy
services were combined. Over twice as many clients quit who received specialist group and specialist
one-to-one behavioural support than clients who received general practitioner and pharmacy based
behavioural support (quit rates were 12.1% (95% CI 10.5–13.8) 10.2% (95% CI 7.6–13.7) and 5.1% (95% CI
2.8–9.3) respectively). After taking into account client and service characteristics, the odds of quitting
were three times higher among group clients and two times higher among clients who received
specialist one-to-one support compared with general practitioner and pharmacy based support
(adjusted odds ratios (ORs) 3.4 (95% CI 1.7–6.7) and 2.3 (95% CI 1.2–4.6) respectively).
There were no significant differences by location. The New Year period was the most successful
time of year for quitting smoking long-term (quit rate 13.1% (95% CI 5.1–29.6)) and this was significantly
more successful than the summer holiday period (quit rate 6.3% (95% CI 4.4–8.9) adjusted OR 1.7
(95% CI 1.0–2.9)).
3.2.2. Sociodemographic Characteristics
Older clients were more likely to quit for each year of age that the increased odds ratio of quitting
was 1.011 (95% CI 1.002–1.020). Affluent clients were more likely to quit than socioeconomically
disadvantaged clients (quit rates 10.3% (95% CI 8.4–12.7) and 6.2% (95% CI 5.0–7.7) respectively,
(adjusted OR 1.4 (95% CI 1.1–1.9)). The mean wellbeing score of quitters was 59.3 out of 100 (95% CI
56.5–62.1) which was significantly higher than the score for non-quitters which was 52.7 out of 100
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(95% CI 51.4–53.9) for non-quitters (adjusted OR 1.007 (95% CI 1.0003–1.013)). Gender differences
did not reach significance in multivariable modelling and ethnicity was eliminated by the backwards
stepwise procedure.
Table 2. ELONS 52-week raw and weighted CO validated quit rates at 52 weeks (percents and 95%
confidence interval (CI)), weighted mean age and wellbeing (and weighted 95% CI) and adjusted odds
ratios from multivariable logistic regression model of CO validated quitting.
N % Quit Rate Weighted QuitRate (95% CI)
Multivariable Logistic
Regression OR (95%CI)
Total 3057 100 9.3 7.7 (6.6–9.0)
Behavioural support (truncated)
group specialist 652 21.3 11.8 12.1 (10.5–13.8) 3.4 (1.7–6.7)
drop in specialist 887 29.0 7.9 7.6 (5.1–11.0) 1.7 (0.9–3.5)
one-to-one specialist 1131 37.0 10.4 10.2 (7.6–13.7) 2.3 (1.2–4.6)
general practice or pharmacy service 366 12.0 4.9 5.1 (2.8–9.3) 1.0
other or unknown 21 0.7 9.5 Not available 2.3 (0.5–11.6)
Location
1 273 8.9 7.7 6.6 (3.9–11.1) 1.0
2 741 24.2 10.4 8.1 (6.4–10.3) 1.1 (0.6–2.1)
3 88 2.9 11.4 11.0 (5.7–20.2) 1.3 (0.5–3.3)
4 396 13.0 10.9 9.3 (6.3–13.5) 1.2 (0.6–2.3)
5 74 2.4 5.4 4.2 (1.3–12.6) 0.7 (0.2–2.4)
6 690 22.6 10.0 7.8 (5.0–11.9) 0.7 (0.4–1.2)
7 146 4.8 6.2 6.4 (3.3–12.2) 0.9 (0.3–2.3)
8 555 18.2 8.3 8.0 (5.9–10.7) 1.1 (0.5–2.1)
9 94 3.1 6.4 11.9 (4.2–29.5) 0.9 (0.3–2.6)
Recruitment date
other months 767 25.1 9.5 7.0 (5.2–9.4) 1.2 (0.8–1.7)
Summer—July, Aug 970 31.7 8.1 6.3 (4.4–8.9) 1.0
back to school—Sept, Oct 1128 36.9 9.7 8.7 (6.4–11.7) 1.2 (0.9–1.6)
New Year—Jan, Feb 192 6.3 12.5 13.1 (5.1–29.6) 1.7 (1.0–2.9)
Age (weighted mean (years)) not quit 43.3 (42.5–44.1)quit 46.8 (44.4–49.2) 1.011 (1.002–1.020)
Gender
female 1710 55.9 8.5 7.2 (6.0–8.5) 1.0
male 1347 44.1 10.4 8.4 (6.8–10.2) 1.2 (0.9–1.5)
Ethnicity
white British 2866 93.8 9.4 7.4 (6.1–9.0) not entered
other white 69 2.3 10.1 11.5 (4.5–26.0)
Asian (including mixed white and Asian) 64 2.1 3.1 3.6 (1.3–9.5)
Other and unknown 58 1.9 12.1 21.6 (7.0–50.1)
SES
0–1 indicators of low ses 1123 36.7 13.0 10.3 (8.4–12.7) 1.4 (1.1–1.9)
2–5 indicators of low ses 1934 63.3 7.2 6.2 (5.0–7.7) 1.0
WHO_5 Wellbeing (weighted mean) not quit 52.7 (51.4–53.9)quit 59.3 (56.5–62.1) 1.007 (1.0003–1.013)
Medication in week 1
varenicline not recorded 1661 54.3 6.7 6.2 (4.9–7.7) 1.0
took varenicline 1396 45.7 12.4 10.0 (7.2–13.8) 1.7 (1.3–2.3)
Dependence
other 1681 55.0 11.4 9.8 (7.7–12.4) 1.5 (1.1–1.9)
highly dependent 1376 45.0 6.8 4.9 (2.9–8.2) 1.0
Determination to quit not entered
other 328 10.7 7.6 5.9 (4.3–8.0)
very/extremely determined 2729 89.3 9.5 8.0 (6.7–9.5)
Support from spouse partner
other 1507 49.3 7.3 6.2 (4.5–8.5) 1.0
support from spouse/partner 1550 50.7 11.3 9.2 (7.4–11.3) 1.4 (1.0–1.8)
Friends and family
other 771 25.2 4.7 3.4 (2.6–4.4) 1.0
half or fewer smoke 2286 74.8 10.9 9.1 (7.5–10.9) 2.0 (1.4–2.9)
SES: socioeconomic status.
Int. J. Environ. Res. Public Health 2016, 13, 1175 8 of 12
3.2.3. Smoking and Quit Attempt Characteristics
Quit rates were higher among clients who started a quit attempt taking varenicline (quit rate
10.0% (95% CI 7.2–13.8) compared with 6.2% (95% CI 4.9–7.7) adjusted OR 1.7 (95% CI 1.3–2.3)), clients
who were less dependent on tobacco (quit rate 9.8% (95% CI 7.7–12.4) compared with 4.9% (95% CI
2.9–8.2), adjusted OR 1.5 (95% CI 1.1–1.9)), clients whose quit attempt was supported by a spouse or
partner (quit rate 9.2% (95% CI 7.4–11.3) compared with 6.2% (95% CI 4.5–8.5), adjusted OR 1.4 (95% CI
1.0–1.8)) and clients whose social network contained fewer smokers (9.1% (95% CI 7.5–10.9) compared
with 3.4% (95% CI 2.6–4.4)) (adjusted OR 2.0 (95% CI 1.4–2.9)). Determination to quit was eliminated
by the backwards stepwise procedure.
4. Discussion
This study provides new evidence that government funded stop-smoking programmes do enable
smokers to quit long-term. The long-term quit rate of smokers who do not participate in a programme
is approximately 3% [34] which is lower than the overall quit rate here (8%) and particularly lower
than those of the specialist one-to-one and group services (10% (95% CI 8%–11%) and 12% (95% CI
11%–14%) respectively). Consistent with a growing number of studies [3,16,35,36], the most effective
behavioural support was provided by specialist advisors. This implies that service commissioners
need to continue to invest in this type of provision to deliver better outcomes for smokers trying
to quit.
Why might the specialist provision be superior? There is emerging data that general practices and
pharmacies may lack the resources to monitor clients sufficiently and develop their services [16,37,38].
Additional financial incentives may also be needed to encourage busy staff with multiple roles to
prioritise smoking cessation above other tasks [38]. General practice staff are under increasing pressure
due to declining funding and a growing population in the UK [39]. Thus, time pressure may be too
great to ensure quality behavioural support, even with extra resources in place [37]. Thus, it may be
preferable for GP practice and pharmacy employees to offer only brief support to use stop-smoking
medication and refer to specialist services if the smoker would like behavioural support to stop.
Nevertheless, this study did not include a cost effectiveness element and only 12% of the sample were
GP practice and pharmacy clients. A previous study of pharmacy services in Glasgow did conclude
that they were cost effective [3]. Thus, further research is needed.
Overall, results were consistent with some longer-term routine monitoring data from services
in other parts of the UK outside England. For example, a self-report quit rate of 15% was similar to
Northern Ireland and lower than Wales where groups predominate, and higher than Scotland where
behavioural support provided in pharmacies is the dominant service model.
The longer-term CO validated quit rate in this study was somewhat lower than the previous
evaluation of the English SSS conducted a decade before our research. The main difference was in
loss to follow-up. This may not only reflect an increase in non-quitters. Since 2002, many people
have moved from landline telephones to mobile telephones [40]. People tend to change their mobile
phone number much more frequently than a landline number [41], thus participant contact phone
numbers are more likely to change between baseline and follow-up. Additionally, refusal rates are
higher [42]. For the telephone 52-week follow-up, 8% had moved, died or were no longer capable
of being interviewed, 5% refused and 24% did not answer or were unavailable. This may have
been exacerbated by a market research company undertaking the ELONS study long-term follow-up
whereas initial contact for the follow-up in the previous evaluation was conducted by SSS staff who
already had a rapport with clients.
4.1. Limitations
This was an observational study, thus there may have been unmeasured confounders and we need
to be cautious about attributing causality. Nevertheless, it is important to study smoking cessation
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in real-world settings. Due to confounding with location, we were unable to include NRT in the
analysis, so it is possible that some of the variation between specialist and GP and pharmacy based
services could have been due to variation in use of NRT. Preliminary analysis suggested that single
NRT and combination NRT were not strongly associated with high quit rates in this study, when
compared with varenicline [33]. However, given that varenicline was included, this may have captured
the variance that some SSS were using perhaps less NRT in favour of more varenicline. There was
lower recruitment to the prospective study than we anticipated. Since our last study, the required
length and complexity of the consent process grew and this seems to have deterred both smoking
cessation advisors and clients from participating. Additionally, the services were undergoing a period
of change which included redundancies and reduced working conditions which may have reduced
motivation among advisors. Weighting quit rates and multivariable analysis helped overcome a lower
than expected response rate.
4.2. Impact
ELONS results can also be used to estimate that 36,249 smoking-related premature deaths were
prevented as a result of English stop-smoking services in the financial year 2012–2013, given that
724,247 quit dates were set, 8% of ELONS participants were abstinent at one year, 35% of those
were abstinent for one-year relapse [43] and half of regular smokers die prematurely from smoking
related diseases.
5. Conclusions
The English stop-smoking services are still helping large numbers of smokers to quit long-term.
The specialist services, particularly group services, appear to be most successful and offer smokers the
best chance of success in their quit attempt. Continued delivery of stop-smoking services forms an
important part of comprehensive tobacco control.
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